ArticleEuropean journal of clinical pharmacology2017
Utilization of chi-square statistics for screening adverse drug-drug interactions in spontaneous reporting systems.
Article in European journal of clinical pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Assessing the risk of adverse drug events from combining aromatase inhibitors with CDK4/6 inhibitors using the FAERS and JADER databases.Frontiers in medicine · 2026Article
- Seizures associated with clozapine augmentation by other antipsychotics: a pharmacovigilance-pharmacodynamic analysis using VigiBase.Therapeutic advances in psychopharmacology · 2026Article
- Exploring the risk of adverse drug events in combination with antiparkinsonics and antipsychotics-a two-decade real-world pharmacovigilance analysis based on the FAERS database.The international journal of neuropsychopharmacology · 2025Article
- Detection of Clinically Significant Drug-Drug Interactions in Fatal Torsades de Pointes: Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System.Journal of medical Internet research · 2025Article
- Article
- Adverse drug reaction signal detection via the long short-term memory model.Frontiers in pharmacology · 2025Article
- Clinical drug interactions between linezolid and other antibiotics: For adverse drug event monitoring.Pharmacology research & perspectives · 2024Article
- Multivariate generalized mixed-effects models for screening multiple adverse drug reactions in spontaneous reporting systems.Frontiers in pharmacology · 2024Article
- Clinical drug interactions between voriconazole and 38 other drugs: a retrospective analysis of adverse events.Frontiers in pharmacology · 2024Article
- Article
- The role of antipsychotics and other drugs on the development and progression of neuroleptic malignant syndrome.Scientific reports · 2023Article
- Detecting Drug-Drug Interactions in COVID-19 Patients.Studies in health technology and informatics · 2022Article
- Verification of the "Upward Variation in the Reporting Odds Ratio Scores" to Detect the Signals of Drug-Drug Interactions.Pharmaceutics · 2021Article
- Improved Detection Criteria for Detecting Drug-Drug Interaction Signals Using the Proportional Reporting Ratio.Pharmaceuticals (Basel, Switzerland) · 2020Article
- Subset Analysis for Screening Drug-Drug Interaction Signal Using Pharmacovigilance Database.Pharmaceutics · 2020Article
- Comparison of Signal Detection Algorithms Based on Frequency Statistical Model for Drug-Drug Interaction Using Spontaneous Reporting Systems.Pharmaceutical research · 2020Article
- Review of Statistical Methodologies for Detecting Drug-Drug Interactions Using Spontaneous Reporting Systems.Frontiers in pharmacology · 2019Review
- SignalDetDDI: An SAS macro for detecting adverse drug-drug interactions in spontaneous reporting systems.PloS one · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWe proposed a statistical criterion to detect drug-drug interactions causing adverse drug reactions in spontaneous reporting systems.
methodsThe used criterion quantitatively measures the discrepancy between the observed and expected number of adverse events via chi-square statistics. We compared the performance of our method with that of Norén et al. (Stat Med 2008; 27 (16): 3057-3070) through a simulation study.
resultsWhen the number of events for a combination of two drugs was equal to or lower than two, the false positive rate for our method ranged from 0.01 to 0.08, whereas the rate for Norén's method ranged from 0.01 to 0.06. The sensitivity for our method ranged from 0.09 to 0.29, whereas the sensitivity for Norén's method ranged from 0.03 to 0.24. The area-under-the-receiver operating characteristic curve for our method was significantly larger than that for Norén's methods regardless of simulation settings. The proposed method was also applied to the Food and Drug Administration Adverse Event Reporting System database, and a recognized drug-drug interaction was detected.
conclusionsThe proposed criterion controlled false positives at an acceptable level and had higher sensitivity than that of Norén's method had when events were rare.
Indexed as
Identifiers
28280890What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.